To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.
Transfusion-associated iron overload induces systemic toxicity. Recently, deferasirox, a convenient long acting oral agent, has been introduced in clinical practice with promising efficacy. However, some patients experience drug-related toxicities and cannot tolerate it. To investigate effect of genetic variations on the toxicities and find optimal target population, we planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase 1A (UGT1A) subfamily, multi-drug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) among pediatric patients received deferasirox.
Study Type
OBSERVATIONAL
Enrollment
100
Seoul National University Hospital
Seoul, Chongno-gu, South Korea
Genetic polymorphism associated with side effects of deferasirox
Genetic polymorphism associated with side effects of deferasirox \- Side effects: Increased AST or ALT \> 5 x ULN or increased bilirubin \> 3 x ULN which was thought to be caused by deferasirox Serum creatinine level increase \> 50% above the baseline value. * Biospecimen Retention: Samples With DNA * Candidate genes exhibit polymorphisms and encodes proteins that are involved in the pharmacokinetics and pharmacodynamics of deferasirox. Candidate genes : MRP2, BCRP, UGT1A subfamily
Time frame: up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.